CoChat

Sustained Improvement of Muscle Function One Year After Full-Length Dystrophin Gene Transfer into mdx Mice by a Gutted Helper-Dependent Adenoviral Vector

Dudley, Roy W.R., Lu, Yifan, Gilbert, Rénald, Matecki, Stefan, Nalbantoglu, Josephine, Petrof, Basil J., Karpati, George · 2004 · Human Gene Therapy
Cited by 72

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Dystrophin gene transfer using helper-dependent adenoviral vectors (HDAd) deleted of all viral genes is a promising option to treat muscles in Duchenne muscular dystrophy (DMD). Previously, we reported high-level dystrophin expression and functional correction of dystrophin-deficient (mdx) mouse muscle 60 days after gene transfer with an HDAd encoding two full-length murine dystrophin cDNAs (referred to as HDCBDysM). In the present study, we tested the long-term efficacy of HDCBDysM by examining muscle contractility parameters and the stability of dystrophin expression 1 year after injection into neonatal mdx muscles. At this point, HDCBDysM-treated muscles averaged 52% dystrophin-positive fibers. Treated muscles also displayed significantly greater isometric force production as well as greater resistance to the force deficits and damage caused by eccentric contractions. The level of protection against eccentric contraction-induced force deficits correlated with the percentage of dystrophin-positive fibers. Furthermore, HDCBDysM treatment restored the dystrophin-glycoprotein complex (DGC) to the sarcolemma and improved other aspects of mdx muscle histopathology examined (central nucleation, muscle hypertrophy, and mononuclear [phagocytic] cell infiltration). These improvements occurred despite the induction of a humoral response against murine dystrophin. Our results indicate that major therapeutic benefits of HDCBDysM are maintained for a long period of the animals' lifespan and suggest that HDCBDys holds promise for treating DMD by gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/104303404772679959

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 72

Metadata

Authors
Dudley, R. W. R., Lu, Y., Gilbert, R., Matecki, S., Nalbantoglu, J., Petrof, B. J., & Karpati, G.
Venue
Human Gene Therapy
Published
2004-02
Volume
15
Issue
2
Pages
145-156
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2002037947
Cited by
72
References
4
FWCI
4.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained Improvement of Muscle Function One Year After Full-Length Dystrophin Gene Transfer into mdx Mice by a Gutted Helper-Dependent Adenoviral Vector. https://app.cochat.ai/papers/10.1089/104303404772679959
The paper
Dudley, R. W. R., Lu, Y., Gilbert, R., Matecki, S., Nalbantoglu, J., Petrof, B. J., & Karpati, G. (2004). Sustained Improvement of Muscle Function One Year After Full-Length Dystrophin Gene Transfer into mdx Mice by a Gutted Helper-Dependent Adenoviral Vector. Human Gene Therapy. https://doi.org/10.1089/104303404772679959

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.